Gyre Therapeutics, Inc.
DE ˙ DB ˙ US4037831033
4,86 € ↑0,12 (2,53%)
2026-06-04
DEL PRIS
SecurityDE:L9S / Gyre Therapeutics, Inc.
InstitutionNorthern Trust Corp
Latest Disclosed Ownership133,841 shares
Latest Disclosed Value $ 932,872
Northern Trust Corp reports 3.87% increase in ownership of L9S / Gyre Therapeutics, Inc.

On May 14, 2026 - Northern Trust Corp filed a 13F-HR form disclosing ownership of 133,841 shares of Gyre Therapeutics, Inc. (DE:L9S) valued at $803,046 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 128,855 shares of Gyre Therapeutics, Inc.. This represents a change in shares of 3.87% during the quarter. The current value of the position is $650,467 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-14 2026-03-31 13F GYRE THERAPEUTICS COM 403783103 133,841 4,986 3.87 933 2.53 0.0000
2026-02-17 2025-12-31 13F GYRE THERAPEUTICS COM 403783103 128,855 12,513 10.76 910 4.84 0.0000
2025-11-14 2025-09-30 13F GYRE THERAPEUTICS COM 403783103 116,342 -26,987 -18.83 868 -17.66 0.0001
2025-08-13 2025-06-30 13F GYRE THERAPEUTICS COM 403783103 143,329 35,319 32.70 1,053 26.41 0.0001
2025-05-13 2025-03-31 13F GYRE THERAPEUTICS COM 403783103 108,010 4,628 4.48 834 -33.36 0.0001
2025-02-14 2024-12-31 13F GYRE THERAPEUTICS COM 403783103 103,382 8,624 9.10 1,251 5.22 0.0002
2024-11-13 2024-09-30 13F GYRE THERAPEUTICS COM 403783103 94,758 62,058 189.78 1,188 204.62 0.0002
2024-08-14 2024-06-30 13F GYRE THERAPEUTICS COM 403783103 32,700 8,632 35.87 390 -7.14 0.0001
2024-05-14 2024-03-31 13F GYRE THERAPEUTICS COM 403783103 24,068 -546 -2.22 421 -33.54 0.0001
2024-02-13 2023-12-31 13F GYRE THERAPEUTICS COM 403783103 24,614 24,614 632 0.0001
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.